CDC panel says AstaZeneca's flu spray vaccine is ineffective, rejects its use next flu season

Modern Healthcare (complimentary online subscription): An expert panel on Wednesday recommended the nasal form of the influenza vaccine should not be used for the upcoming flu season due to its lack of effectiveness over the past three years. Manufacturer AstraZeneca, which generated more than $200 million in sales of FluMist in fiscal year 2015, will take a financial hit.

Read article